Previous Page
28 nanotimes Companies Facts
Nanosphere, Inc. (NASDAQ: NSPH) announced the US Food and Drug Administration has granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on the automated sample-to-result Veri-gene(R) System. The BC-GP test notably expands Nanosphere‘s infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat. The BC-GP test also detects several crucial markers for antimicrobial resistance, including the mecA, vanA, and vanB genes, which confer resistance to the antibiotics methicillin/oxacillin and vancomycin. Rapid detection of these antimicrobial resistance markers provides vital information for clinicians to determine the best treatment for bloodstream infections.
Nanostart Asia Pacific (Nanostart, OTCQX: NASRY) is increasing its share in the Singaporean company Membrane Instruments and Technologies Pte Ltd (MINT) from 18% to 28%. The investment in MINT will take place through the Nanostart Early Stage Venture Fund I, which is managed by Nanostart Asia Pacific. The funds will flow in particular to additional marketing of the Membrane Integrity Sensor and its international rollout. The Membrane Integrity Sensor is currently the flagship product from MINT. It is a sensitive analysis system for continuous and reliable online monitoring of water quality at water treatment facilities. The system was developed at the Nanyang Technological University in Singapore and introduced to the market last year. As the first MINT product available on the market, the sensor is already in use at several facilities. The public water supplier (Public Utilities Board) in Singapore is a customer.
http://www.nanostart-asia-pacific.com
The NanoSteel® Company, a leader in nano-structured steel materials design, announced the development of new advanced high-strength steels with exceptional combinations of strength and ductility for automotive structures. NanoSteel has developed three classes of steel with measured strength/elongation performance of 950 MPa/35%, 1200 MPa/30% and 1600 MPa/15% respectively.
NanoString Technologies, Inc., announced the initiation of the second clinical validation study of its PAM50-based breast cancer assay. The new study will evaluate samples from more than 1,000 patients enrolled in the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG8) trial to test the ability of NanoString’s assay to estimate the prognosis of postmenopausal women with hormone receptor-positive early-stage breast cancer. The ABCSG8 study, initiated in 1996, demonstrated that compared to treatment with tamoxifen alone, sequential adjuvant treatment with tamoxifen followed by anastrozole in postmenopausal women with